Fiche publication
Date publication
janvier 2015
Journal
Experimental hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr OJEDA-URIBE Mario
Tous les auteurs :
Tardy MP, Gastaud L, Ojeda-Uribe M, Boscagli A, Caruso S, Skaf R, Gutnecht J, Thyss A, Peyrade F
Lien Pubmed
Résumé
Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently carmustine availability became difficult. The purpose of this study was to evaluate the feasibility and the safety of replacing carmustine by bendamustine in a new Z-BeEAM regimen (ibritumomab tiuxetan, bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation.
Référence
Exp Hematol Oncol. 2015 ;4:18
